Literature DB >> 11070332

Estradiol levels in psychotic disorders.

T J Huber1, J Rollnik, J Wilhelms, A von zur Mühlen, H M Emrich, U Schneider.   

Abstract

Estradiol has been postulated to constitute a protective factor for schizophrenia, which could provide women at risk to experience a psychotic episode with a relative protection in phases of high estradiol levels, i.e. before menopause and during the peri- and postovulatory phases of their cycle. Women suffering from schizophrenia have been reported to show significantly lower estradiol levels than the normal population and to experience first onset or recurrence of a psychotic episode significantly more often in low estrogen phases of the cycle with low estradiol levels. We examined estradiol levels in an open prospective study in 43 women admitted with a diagnosis of an acute psychotic episode and could confirm these findings for schizophrenia as well as other psychotic disorders. Only 28% of the women exhibited estradiol and progesterone levels indicating a peri- or postovulatory phase and all of the estradiol levels on admission were either within the lower part of the cycle-dependent normal range or below normal; comparison with a control group of healthy volunteers and patients admitted with different psychiatric diagnoses confirmed their estradiol levels to be significantly higher. However, when splitting this control group, the statistical difference would only hold between the study group of psychotic patients and the healthy control group. The group of patients with other diagnoses than a psychotic episode fell in between of the other two groups and did not differ significantly from either. Thus, an unspecific effect, i.e. a hypothalamic downregulation due to the stress of acute hospitalization must be born in mind when assessing hormone levels in acutely psychotic women.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11070332     DOI: 10.1016/s0306-4530(00)00034-2

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  26 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

2.  Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV.

Authors:  Nancy A Hessol; Susan Holman; Howard Minkoff; Mardge H Cohen; Elizabeth T Golub; Seble Kassaye; Roksana Karim; Oluwakemi Sosanya; Christopher Shaheen; Zaher Merhi
Journal:  AIDS Care       Date:  2015-08-14

3.  Gender effects on brain changes in early-onset psychosis.

Authors:  Marta Rapado-Castro; Cali F Bartholomeusz; Josefina Castro-Fornieles; Ana González-Pinto; Soraya Otero; Inmaculada Baeza; Carmen Moreno; Montserrat Graell; Joost Janssen; Nuria Bargalló; Christos Pantelis; Manuel Desco; Celso Arango
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-01-15       Impact factor: 4.785

Review 4.  Neuropsychiatric effects of tamoxifen: Challenges and opportunities.

Authors:  Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck
Journal:  Front Neuroendocrinol       Date:  2020-08-18       Impact factor: 8.606

5.  Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice.

Authors:  Marie A Labouesse; Wolfgang Langhans; Urs Meyer
Journal:  Psychopharmacology (Berl)       Date:  2015-04-18       Impact factor: 4.530

6.  Timing of menarche and abnormal hippocampal connectivity in youth at clinical-high risk for psychosis.

Authors:  Katherine S F Damme; Ivanka Ristanovic; Teresa Vargas; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2020-04-30       Impact factor: 4.905

7.  Amphetamine sensitization in reproductively experienced female rats.

Authors:  John J Byrnes; Robert S Bridges; Elizabeth M Byrnes
Journal:  Neurosci Lett       Date:  2011-07-30       Impact factor: 3.046

8.  Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.

Authors:  Judith Usall; Elena Huerta-Ramos; Javier Labad; Jesús Cobo; Christian Núñez; Marta Creus; Gemma García Parés; Daniel Cuadras; José Franco; Eva Miquel; Julio César Reyes; Mercedes Roca
Journal:  Schizophr Bull       Date:  2015-11-20       Impact factor: 9.306

9.  Progesterone reduces hyperactivity of female and male dopamine transporter knockout mice.

Authors:  Cheryl A Frye; Ichiro Sora
Journal:  Behav Brain Res       Date:  2010-01-20       Impact factor: 3.332

Review 10.  Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.

Authors:  Uriel Halbreich
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.